PPARG Antikörper (pSer273)

Produktnummer ABIN1387919

Der Kaninchen Polyklonal Anti-PPARG-Antikörper wurde für WB, ELISA, ICC, IF (cc), IF (p), IHC (p) und IHC (fro) validiert. Er ist geeignet, PPARG in Proben von Human, Maus, Ratte, Schaf und Meerschweinchen zu detektieren. Es sind 10+ Publikationen verfügbar.

Kurzübersicht für PPARG Antikörper (pSer273) (ABIN1387919)

Target: PPARG (Peroxisome Proliferator-Activated Receptor gamma (PPARG))

Reaktivität: Human, Maus, Ratte, Schaf, Meerschweinchen

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PPARG Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunocytochemistry (ICC), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Produktdetails anti-PPARG Antikörper

Bindungsspezifität: pSer273

Kreuzreaktivität: Meerschweinchen, Human, Maus, Ratte, Schaf

Homologie: Cow,Chicken,Rabbit

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic phosphopeptide derived from human PPAR Gamma around the phosphorylation site of ser273

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Referenzen für anti-PPARG Antikörper (ABIN1387919)

Liu, Wan, Lang, Si, Zhu, Zhou, Mi: "Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resistance without excessive weight gain in Zucker diabetic fatty rats." in: Molecular and cellular endocrinology, Vol. 439, pp. 105-115, (2018) (PubMed).

Liu, Zhou, Lang, Zhou, Mi: "Dihydromyricetin enhances glucose uptake by inhibition of MEK/ERK pathway and consequent down-regulation of phosphorylation of PPARγ in 3T3-L1 cells." in: Journal of cellular and molecular medicine, Vol. 22, Issue 2, pp. 1247-1256, (2017) (PubMed).

Abd Alla, Graemer, Fu, Quitterer: "Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice." in: The Journal of biological chemistry, Vol. 291, Issue 6, pp. 2583-600, (2016) (PubMed).

Agrawal, Chanley, Westbrook, Nie, Kitao, Guess, Benndorf, Hidalgo, Smoyer: "Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome." in: Scientific reports, Vol. 6, pp. 24392, (2016) (PubMed).

Maganti, Tersey, Syed, Nelson, Colvin, Maier, Mirmira: "Peroxisome Proliferator-activated Receptor-γ Activation Augments the β-Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β Cell Death in Non-obese Diabetic Mice." in: The Journal of biological chemistry, Vol. 291, Issue 43, pp. 22524-22533, (2016) (PubMed).

Stechschulte, Ge, Hinds, Sanchez, Franceschi, Lecka-Czernik et al.: "Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 ..." in: The Journal of biological chemistry, Vol. 291, Issue 47, pp. 24475-24486, (2016) (PubMed).

Liu, Feng, Zhu, Liu, Han, Chen, Wang, Li, Li, Xu, Si: "Identification of a novel selective agonist of PPAR? with no promotion of adipogenesis and less inhibition of osteoblastogenesis." in: Scientific reports, Vol. 5, pp. 9530, (2015) (PubMed).

Kolli, Stechschulte, Dowling, Rahman, Czernik, Lecka-Czernik: "Partial agonist, telmisartan, maintains PPAR? serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass." in: PLoS ONE, Vol. 9, Issue 5, pp. e96323, (2014) (PubMed).

Pandurangan, Park, Kim: "Aspartame downregulates 3T3-L1 differentiation." in: In vitro cellular & developmental biology. Animal, Vol. 50, Issue 9, pp. 851-7, (2014) (PubMed).

Sarr, Thompson, Zhao, Lee, Regnault: "Low birth weight male guinea pig offspring display increased visceral adiposity in early adulthood." in: PLoS ONE, Vol. 9, Issue 6, pp. e98433, (2014) (PubMed).

Details zu PPARG

Target: PPARG (Peroxisome Proliferator-Activated Receptor gamma (PPARG))

Andere Bezeichnung: PPAR Gamma

Hintergrund:

Synonyms: GLM1, CIMT1, NR1C3, PPARG1, PPARG2, PPARgamma, Peroxisome proliferator-activated receptor gamma, PPAR-gamma, Nuclear receptor subfamily 1 group C member 3, PPARG

Background: Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.

Gen-ID: 5468

UniProt: P37231

Pathways: MAPK Signalweg, Nuclear Receptor Transcription Pathway, Steroid Hormone Mediated Signaling Pathway, Negative Regulation of Hormone Secretion, Carbohydrate Homeostasis, Regulation of Lipid Metabolism by PPARalpha, Positive Regulation of Endopeptidase Activity, Brown Fat Cell Differentiation, Positive Regulation of fat Cell Differentiation